ERBB2 and breast carcinoma: The existence of IGF-IR/ErbB2 heterodimers has also been established and this association was shown to contribute to Herceptin resistance in human breast cancer cell lines; this interaction could be disrupted by treating with monoclonal antibody based therapy to IGF-IR [38].